• / Free eNewsletters & Magazine
  • / My Account
Home>Sanofi, Myokardia Team Up to Work on Genetic Heart Disease

Sanofi, Myokardia Team Up to Work on Genetic Heart Disease

3party Content

Wed, 17 Sep 2014

By Inti Landauro PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) Wednesday said it teamed up with closely held Myokardia to develop therapies for genetic heart diseases, called cardiomyopathies. The two companies will make as much as $200 million on combined investment by 2018, Sanofi said.
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.